Literature DB >> 7471615

Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.

T P Sloan, J R Idle, R L Smith.   

Abstract

Eleven subjects of previously determined debrisoquine oxidation phenotype status (extensive metabolizer [EM], n = 5; poor metabolizer [PM], n = 6) were studied for their ability to perform the aromatic 4-hydroxylation of phenytoin. The PM subjects studied were found to be slower metabolizers of phenytoin than EM subjects in terms of the metabolite formation rate constant (kfHPPH: EM, 0.030 +/- .007 hr-1; PM, 0.016 +/- 0.003 hr-1, 2p less than 0.001) and cumulative excretion of 4-hydroxyphenytoin (48 hr after dosing: EM, 52.8 +/- 10.7%; PM, 36.9 +/- 7.0%, 2p less than 0.01). It is concluded that the metabolic oxidation of phenytoin is influenced by the same DH and DL alleles, acting at the same locus, that regulate the hydroxylation of debrisoquine and that impaired metabolism of phenytoin may be expected to occur in about 9% of the population, being transmitted as an autosomal-recessive trait. It is suggested that debrisoquine oxidation phenotyping may have predictive value in guiding phenytoin dosage, particularly in those with impaired oxidation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7471615     DOI: 10.1038/clpt.1981.68

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

1.  Lack of defect in oxidative hydroxylation of debrisoquine in a patient with halothane hepatitis.

Authors:  M Toutoungi; D Magnenat
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Differential effect of continuous administration of beta-adrenoceptor antagonists on antipyrine and phenytoin clearance.

Authors:  H Perrild; L Kayser; H E Poulsen; L Skovsted; B Jørgensen; J M Hansen
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

3.  Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents.

Authors:  P Dayer; L Balant; A Küpfer; F Courvoisier; J Fabre
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

5.  Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers.

Authors:  P Dayer; A Kubli; A Kupfer; F Courvoisier; L Balant; J Fabre
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

6.  The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.

Authors:  H W Devonshire; I Kong; M Cooper; T P Sloan; J R Idle; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

Review 7.  Assessment of methods to identify sources of interindividual pharmacokinetic variations.

Authors:  E S Vesell; M B Penno
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

8.  Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.

Authors:  E L Carey; H J Duff; D M Roden; R K Primm; G R Wilkinson; T Wang; J A Oates; R L Woosley
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

9.  Polymorphic hydroxylation of perhexiline maleate in man.

Authors:  R G Cooper; D A Evans; E J Whibley
Journal:  J Med Genet       Date:  1984-02       Impact factor: 6.318

10.  Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.

Authors:  G C Kahn; A R Boobis; S Murray; M J Brodie; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.